PD-1 inhibitor exposure, hepatic metastasis and independent prognostic factors in recurrent or metastatic esophageal cancer: a single-center retrospective cohort study

Background PD-1 inhibitor-based chemoimmunotherapy is now standard first-line treatment for advanced esophageal cancer. Real-world data remain scarce, and which clinical variables still carry prognostic weight once immunotherapy is routine is not settled. Methods Consecutive patients with recurrent or initial metastatic esophageal cancer treated at our center, who had received at least one line of systemic therapy and had complete follow-up, were reviewed. Overall survival (OS) and progression-free survival (PFS) were both measured from the diagnosis of recurrent or metastatic disease, when first-line therapy began, and groups were compared by the log-rank test. Prognostic factors were examined by Cox regression stratified by disease setting, together with subgroup and sensitivity analyses. Results Seventy-eight patients were analyzed (median age 62 years; 82.1% male; 80.8% squamous; 46 initial metastatic). 53 of the 73 patients with known exposure (72.6%) had received a PD-1 inhibitor. Median follow-up was 39.4 months, median OS was 24.4 months (95% CI 17.7-32.6) and median PFS 9.3 months (95% CI 7.5-15.8). PD-1 exposure raised the objective response rate (43.4% vs 5.0%; P = 0.002) without improving OS (adjusted HR 1.39) or PFS (adjusted HR 0.78), and stricter definitions of exposure and landmark analyses left these estimates unchanged. Liver metastasis was the only variable associated with both endpoints after adjustment (OS HR 2.97, 95% CI 1.42-6.19; PFS HR 2.38, 95% CI 1.15-4.92), and the association was at least as strong among the 63 patients with squamous cell carcinoma (OS HR 4.18). PD-1 exposure was associated with longer PFS in an exploratory analysis of the 45 patients with initialmetastatic disease (adjusted HR 0.36, 95% CI 0.14-0.93). Conclusions Among the patients with advanced esophageal squamous cell carcinoma included in our study, the median OS was 24.4 months and the median PFS was 9.3 months. Both outcomes exceeded historical real-world data for this setting, supporting the feasibility of routine clinical use of first-line chemoimmunotherapy. PD-1 exposure improved the response rate but not survival, in an observational comparison the likeliest explanation is confounding by indication. Liver metastasis was the strongest independent adverse prognostic factor and indicates the group in greatest need of new treatment options.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-21
DOI
https://doi.org/10.21203/rs.3.rs-11700860/v1
Primary Topic
Esophageal Cancer Research and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

PD-1 inhibitor exposure, hepatic metastasis and independent prognostic factors in recurrent or metastatic esophageal cancer: a single-center retrospective cohort study

Yaqing Dai, Jiancheng Li, Zhou Rui
Research Square
Esophageal Cancer Research and Treatment
preprint

PD-1 inhibitor exposure, hepatic metastasis and independent prognostic factors in recurrent or metastatic esophageal cancer: a single-center retrospective cohort study

Yaqing Dai, Jiancheng Li, Zhou Rui
preprint en

Abstract

Background PD-1 inhibitor-based chemoimmunotherapy is now standard first-line treatment for advanced esophageal cancer. Real-world data remain scarce, and which clinical variables still carry prognostic weight once immunotherapy is routine is not settled. Methods Consecutive patients with recurrent or initial metastatic esophageal cancer treated at our center, who had received at least one line of systemic therapy and had complete follow-up, were reviewed. Overall survival (OS) and progression-free survival (PFS) were both measured from the diagnosis of recurrent or metastatic disease, when first-line therapy began, and groups were compared by the log-rank test. Prognostic factors were examined by Cox regression stratified by disease setting, together with subgroup and sensitivity analyses. Results Seventy-eight patients were analyzed (median age 62 years; 82.1% male; 80.8% squamous; 46 initial metastatic). 53 of the 73 patients with known exposure (72.6%) had received a PD-1 inhibitor. Median follow-up was 39.4 months, median OS was 24.4 months (95% CI 17.7-32.6) and median PFS 9.3 months (95% CI 7.5-15.8). PD-1 exposure raised the objective response rate (43.4% vs 5.0%; P = 0.002) without improving OS (adjusted HR 1.39) or PFS (adjusted HR 0.78), and stricter definitions of exposure and landmark analyses left these estimates unchanged. Liver metastasis was the only variable associated with both endpoints after adjustment (OS HR 2.97, 95% CI 1.42-6.19; PFS HR 2.38, 95% CI 1.15-4.92), and the association was at least as strong among the 63 patients with squamous cell carcinoma (OS HR 4.18). PD-1 exposure was associated with longer PFS in an exploratory analysis of the 45 patients with initialmetastatic disease (adjusted HR 0.36, 95% CI 0.14-0.93). Conclusions Among the patients with advanced esophageal squamous cell carcinoma included in our study, the median OS was 24.4 months and the median PFS was 9.3 months. Both outcomes exceeded historical real-world data for this setting, supporting the feasibility of routine clinical use of first-line chemoimmunotherapy. PD-1 exposure improved the response rate but not survival, in an observational comparison the likeliest explanation is confounding by indication. Liver metastasis was the strongest independent adverse prognostic factor and indicates the group in greatest need of new treatment options.

Research Square
Fujian Medical University (CN)
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon